Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 9, 2015, Pages 1215-1231

  Lin, Wen ^a   Xie, Xiangyang ^b   Yang, Yanfang ^c   Liu, Hui ^b   Fu, Xudong ^b   Chen, Ying ^b   Liu, Hong ^b   Yang, Yang ^d  

^a Huangshi Love and Health Hospital of Hubei Province   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

cell penetrating peptides; NGR targeted; photo sensitive cell penetrating peptides (PSP); small interfering RNA

Indexed keywords

ASPARAGINYLGLYCYLARGININE; CELL PENETRATING PEPTIDE; DISTEAROYLPHOSPHOETHANOLAMINE N MALEIMIDE; GLYCEROPHOSPHOLIPID; LIPOSOME; MACROGOL 2000; MYC PROTEIN; SMALL INTERFERING RNA; TRIPEPTIDE; UNCLASSIFIED DRUG; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); DRUG CARRIER; LIGAND; MACROGOL DERIVATIVE; NANOPARTICLE; NGR PEPTIDE; OLIGOPEPTIDE; PHOSPHATIDYLETHANOLAMINE;

APOPTOSIS; ARTICLE; CANCER CELL; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TARGETING; ENCAPSULATION; ENDOSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ILLUMINATION; IN VITRO STUDY; INTERNALIZATION; INTRACELLULAR TRANSPORT; MCF 7 CELL LINE; PARTICLE SIZE; PHOTOSENSITIVITY; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION; CHEMISTRY; DRUG EFFECTS; PROCEDURES; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CYTOPLASM; DOWN-REGULATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; LIPOSOMES; MCF-7 CELLS; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING;

EID: 84938751755     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12425     Document Type: Article

References (40)

1. Kim DH, Rossi JJ,. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184.
2. Baudino TA, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002; 16: 2530-2543.
3. Li SD, et al. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008; 16: 942-946.
4. Gomes-da-Silva LC, et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 2012; 45: 1163-1171.
5. Fang J, et al. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63: 136-151.
6. Kesharwani P, et al. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2002; 33: 7138-7150.
7. Chandra B, et al. Formulation of photocleavable liposomes and the mechanism of their content release. Org Biomol Chem 2006; 4: 1730-1740.
8. Suzuki R, et al. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release 2009; 133: 198-205.
9. Antipina MN, Sukhorukov GB,. Remote control over guidance and release properties of composite polyelectrolyte based capsules. Adv Drug Deliv Rev 2011; 63: 716-729.
10. Shi NQ, et al. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine 2012; 7: 1613-1621.
11. Bartlett RL 2nd, et al. Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants. Nanomedicine 2013; 9: 419-427.
12. Davis SC, Szoka FC,. Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. Bioconjug Chem 1998; 9: 783-792.
13. Elegbede AI, et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc 2008; 130: 10633-10642.
14. Torchilin VP,. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9: E128-E147.
15. Forman J, et al. Photobiological and thermal effects of photoactivating UVA light doses on cell cultures. Photochem Photobiol Sci 2007; 6: 649-658.
16. Wan XJ, et al. Photo-degradable, protein-polyelectrolyte complex-coated, mesoporous silica nanoparticles for controlled co-release of protein and model drugs. Macromol Rapid Commun 2013; 34: 341-347.
17. Lu J, et al. Light-activated nanoimpeller-controlled drug release in cancer cells. Small 2008; 4: 421-426.
18. Mal NK, et al. Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature 2003; 421: 350-353.
19. Mayer G, Heckel A,. Biologically active molecules with a 'light switch'. Angew Chem Int Ed Engl 2006; 45: 4900-4921.
20. Shamay Y, et al. Light induced drug delivery into cancer cells. Biomaterials 2011; 32: 1377-1386.
21. Dadon Z, et al. Light-induced peptide replication controls logic operations in small networks. Chemistry (Easton) 2010; 16: 12096-12099.
22. Hiraoka T, Hamachi I,. Caged RNase: photoactivation of the enzyme from perfect off-state by site-specific incorporation of 2-nitrobenzyl moiety. Bioorg Med Chem Lett 2003; 13: 13-15.
23. Shirakawa I, et al. Measurement of nucleotide exchange rate constants in single rabbit soleus myofibrils during shortening and lengthening using a fluorescent ATP analog. Biophys J 2000; 78: 918-926.
24. Goedhart J, Gadella TW Jr,. Photolysis of caged phosphatidic acid induces flagellar excision in Chlamydomonas. Biochemistry 2004; 43: 4263-4271.
25. Caldorera-Moore M, et al. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010; 7: 479-495.
26. Hansen MB, et al. Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Control Release 2012; 164: 87-94.
27. Allen TM,. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-763.
28. Garde SV, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007; 18: 1189-1200.
29. Fischer PM, et al. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J Pept Res 2000; 55: 163-172.
30. Yang YF, et al. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 2014; 35: 4368-4381.
31. Xiang B, et al. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 2013; 34: 6976-6991.
32. Gao J, et al. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 2012; 33: 270-282.
33. Haycock JW,. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 2011; 695: 1-15.
34. Kibria G, et al. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 2011; 153: 141-148.
35. Zhang QY, et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 2013; 34: 7980-7993.
36. Gao W, et al. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 2013; 34: 4137-4149.
37. Xu Y, Szoke FC Jr,. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35: 5616-5623.
38. Chen Y, et al. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 2010; 18: 828-834.
39. Tseng YC, et al. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009; 61: 721-731.
40. Mehta G, et al. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 2012; 164: 192-204.